BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15782422)

  • 1. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Duncan GG; Epstein JB; Tu D; El Sayed S; Bezjak A; Ottaway J; Pater J;
    Head Neck; 2005 May; 27(5):421-8. PubMed ID: 15782422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system.
    El-Sayed S; Nabid A; Shelley W; Hay J; Balogh J; Gelinas M; MacKenzie R; Read N; Berthelet E; Lau H; Epstein J; Delvecchio P; Ganguly PK; Wong F; Burns P; Tu D; Pater J
    J Clin Oncol; 2002 Oct; 20(19):3956-63. PubMed ID: 12351592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
    Veness MJ; Foroudi F; Gebski V; Timms I; Sathiyaseelan Y; Cakir B; Tiver KW
    Australas Radiol; 2006 Oct; 50(5):468-74. PubMed ID: 16981945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms.
    Su CK; Mehta V; Ravikumar L; Shah R; Pinto H; Halpern J; Koong A; Goffinet D; Le QT
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):171-7. PubMed ID: 15337553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
    Pow EH; Kwong DL; McMillan AS; Wong MC; Sham JS; Leung LH; Leung WK
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):981-91. PubMed ID: 17145528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia.
    Ringash J; Warde P; Lockwood G; O'Sullivan B; Waldron J; Cummings B
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1403-7. PubMed ID: 15817343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life.
    Elting LS; Keefe DM; Sonis ST; Garden AS; Spijkervet FK; Barasch A; Tishler RB; Canty TP; Kudrimoti MK; Vera-Llonch M;
    Cancer; 2008 Nov; 113(10):2704-13. PubMed ID: 18973181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy.
    Fang FM; Liu YT; Tang Y; Wang CJ; Ko SF
    Cancer; 2004 Jan; 100(2):425-32. PubMed ID: 14716781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
    Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N
    J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.
    Langendijk JA; Doornaert P; Verdonck-de Leeuw IM; Leemans CR; Aaronson NK; Slotman BJ
    J Clin Oncol; 2008 Aug; 26(22):3770-6. PubMed ID: 18669465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy.
    Braam PM; Roesink JM; Raaijmakers CP; Busschers WB; Terhaard CH
    Radiat Oncol; 2007 Jan; 2():3. PubMed ID: 17207274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire.
    Epstein JB; Beaumont JL; Gwede CK; Murphy B; Garden AS; Meredith R; Le QT; Brizel D; Isitt J; Cella D
    Cancer; 2007 May; 109(9):1914-22. PubMed ID: 17377917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
    Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
    Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy.
    Ravasco P; Monteiro-Grillo I; Marques Vidal P; Camilo ME
    Head Neck; 2005 Aug; 27(8):659-68. PubMed ID: 15920748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in quality of life of head-and-neck cancer patients following postoperative radiotherapy.
    Fang FM; Chien CY; Kuo SC; Chiu HC; Wang CJ
    Acta Oncol; 2004; 43(6):571-8. PubMed ID: 15370615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
    Burlage FR; Roesink JM; Kampinga HH; Coppes RP; Terhaard C; Langendijk JA; van Luijk P; Stokman MA; Vissink A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):14-22. PubMed ID: 17869018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.